Acute Erythroleukemia

Get Updates

Dec 06, 2016 www.marketwired.com

ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting – Marketwired
Read More

Connect. Empower. Inspire.

Stay

CONNECTED

Terms & Conditions – Privacy Policy
Contact Us

[email protected]
28 Argonaut, Suite 150
Aliso Viejo, CA 92656
Phone: (+1) 949-248-RARE (7273)

Copyright © 2021 Global Genes.
Global Genes is a non-profit 501(c)(3) corporation advocating for rare disease globally.
EIN: 26-3331487

The like functionality is a member-only feature

You can login here to your account or you can register to start saving, exploring and sharing resources and news. Connect with our community now!

Register to get the latest updates

Please join the RARE Portal to add diseases of interest to your personal profile. By creating a profile, you can receive news, resources and updates related to this disease as well as many other benefits.

Register to share with the community

You must be Corporate Alliance or Foundation Alliance member to contribute resources. Please contact us if you have a resource you’d like us to consider.

Contribute with resources

Alliance or Foundation Alliance member to contribute resources. Please contact us if you have a resource you’d like us to consider.

Be a Guest BLOGGER

Thank you for your interest in becoming in a guest blogger. Please email [email protected] for more information.

Stay Connected

First Name

Last Name

Role in Rare Disease

Acute Erythroleukemia

ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting – Marketwired

Connect. Empower. Inspire.

CONNECTED